Candidate: Antisense oligonucleotides
Type: Antisense oligonucleotides targeting Coronaviridae, including SARS-CoV-2, using Luxna’s nucleic acid technology.
Status: Aligos on April 15 said it was expanding its collaboration with Luxna Biotech to target the genomes of certain families of respiratory viruses, including Coronaviridae, which includes SARS-CoV-2. Aligos licenses Luxna’s modified nucleic acid technology to develop targeted therapies for hepatologic diseases and viral infections through the collaboration, launched in 2018.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
● ANTIVIRAL
● VAX
● ANTIBODY
● RNA
